Navigation Links
3SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results
Date:8/15/2011

kind available in China. The 36,000 IU dosage is comparable to the standardized dose used globally for chemotherapy-induced anemia, allowing for less frequent administration than lower dosage forms, which in turn is expected to provide greater convenience for both patients and caregivers.
  • We formed an investment partnership ("3SBio Ventures" or the "Fund") with Taizhou Oriental CMC Limited ("Taizhou Oriental"), the investment arm of Taizhou China Medical City Company ("CMC"). CMC is a Jiangsu province-based national level high-tech industrial park dedicated to life science innovation and is supported directly by the Ministry of Health, Ministry of Science and Technology and the State Food and Drug Administration. The investment partnership will be managed by Taizhou Huan Sheng Investment Management Company Limited ("Huan Sheng"), a wholly-owned subsidiary of 3SBio. Taizhou Oriental and 3SBio have committed RMB50 million and RMB200 million respectively to the Fund. The initial contribution is 20% of the total commitment with the balance to be drawn down as required. 3SBio Ventures will seek investments in the life science sector that support 3SBio's strategic interests. The Fund will have an investment horizon of 8 years with an option to extend.
  • Dr. David Chen has assumed new responsibilities as the managing partner of 3SBio Ventures and has resigned from his position as chief operating officer of 3SBio Inc. Dr. Chen will focus his efforts on seeking strategic investment opportunities for 3SBio Ventures. Dr. Chen's current responsibilities will be allocated among the senior management team while the Company continues to seek opportunities to strengthen its executive team.
  • Dr. Yingfei Wei has resigned from her position as 3SBio's chief scientific officer but will remain engaged in a consulting role to both 3SBio and 3SBio Ventures. Dr. Dongmei Su, chief technology officer of the company, will take on the role of vice president, R&D and wil
    '/>"/>

  • SOURCE 3SBio Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

    Related medicine technology :

    1. 3SBio Inc. Schedules Unaudited Second Quarter 2011 Results
    2. 3SBio Inc. Announces SFDA Approval of High-Dose EPIAO
    3. 3SBio Announces Conversion of Isotechnika Debenture
    4. 3SBio Inc. Schedules Third Quarter 2010 Unaudited Financial Results
    5. 3SBio Announces Partial Conversion of Isotechnika Debenture
    6. 3SBio Announces Investor Conference Schedule
    7. 3SBio and Isotechnika Pharma Announce Strategic Partnership to Develop and Commercialize Voclosporin in China
    8. 3SBio Inc. Announces Results of Annual General Meeting
    9. NewCardio Announces Financial Results for Its 2011 Second Quarter
    10. Dehaier Medical Announces Record Second Quarter 2011 Financial Results
    11. Emdeon Announces Support for Electronic Prescribing of Controlled Substances Using the DEA-Allowed Quicker-to-Market Approach
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... Texas , Jan. 15, 2014  Humberto C. Antunes,  ... Achievement Award" from the Journal of Drugs in ... & Clinical Conference (ODAC). The event is January 17-20, 2014, at ... Florida . The ODAC is ...
    (Date:1/15/2014)... R.I. , Jan. 15, 2014 MultiCell Technologies, ... filed a U.S. provisional patent application concerning composition of ... to achieve targeted tumor cell death.  ... small noncoding double stranded RNA molecules (VSRNAs) which interfere ...
    (Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... - India Drug Forecast and Market Analysis ... PharmaPoint: Atopic Dermatitis - India ...
    Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
    ... Sept. 28 Open Door Family Medical Centers ... center providing quality health care to the under-served, ... received the HIMSS Community Health Davies Award ... in the implementation and use of health information ...
    ... Sunridge International (OTC Bulletin Board: SNDZ ... ocular hypertension will be introduced in October to eye ... Presentations have been planned by its Indian distributors, New ... – 14.  The company,s Pneumatic Trabeculoplasty (PNT), treatment is ...
    Cached Medicine Technology:Open Door Family Medical Centers Named Top Community Health Center in Nation for Use of Information Technology 2Sunridge to Introduce Their PNT Treatment for Glaucoma to Medical Personnel in India 2
    (Date:4/18/2014)... Johns Hopkins University School of Medicine researchers have been ... for diabetes, Novo Nordisk announced this month. Of the ... and Obesity Biologics Science Forum Program, only four projects ... Hopkins researchers. They are Jonathan Powell, M.D., Ph.D.; G. ... , Jonathan Powell, a professor of oncology, will use ...
    (Date:4/18/2014)... French . ... medicine. A team led by Ludwik Leibler from the ... Didier Letourneur from the Laboratoire Recherche Vasculaire Translationnelle (INSERM/Universits ... the principle of adhesion by aqueous solutions of nanoparticles ... and tissues. This easy-to-use gluing method has been tested ...
    (Date:4/17/2014)... Scientists have identified new pain relief targets that ... pain. BBSRC-funded researchers at King,s College London made ... nerves in the periphery of the body. , ... and identifying mechanisms underlying pain generation and our ... related side effects." , One potential side effect ...
    (Date:4/17/2014)... (April 17, 2014) Two recent papers by ... and colleagues may help scientists develop treatments or ... fever, Japanese encephalitis and other disease-causing flaviviruses. , ... and molecular genetics at the School of Medicine ... Hughes Medical Institute, and colleagues recently published articles ...
    (Date:4/17/2014)... Doctors who treat patients with a severe and ... an agonizing treatment decision. , The drug sirolimus ... relieve shortness of breath. But some patients eventually ... potentially fatal complications following transplantation. , "It,s a ... director of Loyola University Medical Center,s LAM Clinic ...
    Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
    ... Pen ... Technology, ... system, a new innovative solution for,digitally capturing patient information that is ... administer. The Docuscan Patient History solution with Paros(TM) technology enables,digital ...
    ... pop stars are more than twice as likely as the ... within a few years of becoming famous, reveals research published ... Health. , The findings are based on more than 1050 ... fame between 1956 and 1999. , All the musicians featured ...
    ... Steps for Young Children Program, which added behavior ... benefit families more than two years after the ... from the Johns Hopkins Bloomberg School of Public ... Steps included greater satisfaction among parents with their ...
    ... give rise to exuberant scarring, which can lead to ... disfigurement. In a review article in this weeks PLoS ... of Medicine) and colleagues examine the process of such ... the research areas that are likely to lead to ...
    ... ARLINGTON, Va., Aug. 22 The American,Psychiatric Association (APA) ... review of scientific evidence that led to the,approval of ... The APA is pleased that the approvals are a ... which was designed to,encourage research that leads to this ...
    ... safety of blood supply by detecting virus ... earlier in infection cycle., ... & Drug Administration (FDA) today approved its biologics,license application for the ... blood and plasma. West Nile virus, which can,cause serious health issues, ...
    Cached Medicine News:Health News:New 'Smart' Technology Makes Patient Data Collection Easier, More Efficient 2Health News:Pop stars more than twice as likely to die an early death 2Health News:Practice-based intervention has sustained benefits for children and families 2Health News:APA Comments on FDA's First Approval of Medication to Treat Pediatric Schizophrenia and Bipolar Disorder 2Health News:FDA Approves New Roche West Nile Virus Blood Screening Test 2Health News:FDA Approves New Roche West Nile Virus Blood Screening Test 3
    ... American Proficiency Institute offers innovative proficiency ... technical support. As a result, API is ... in the world with over 12,000 laboratories ... advantages of using API:, Paperless ...
    ... APC-R FVL is a new functional test ... for Activated Protein C Resistance caused by ... contrast to other commercially available methods, Pefakit ... C or S, Lupus Anticoagulants, Elevated FVIII ...
    ... is an advanced ophthalmic laser platform, ... technologies, improved operability, fast operation, super ... with versatility for combination laser systems. ... and adds several unique features such ...
    The Properdin ELISA Kit is approved for in-vitro diagnostic use and measurement of properdin serum levels, relevant in cases of recurrent meningococcal infection and recurrent bacterial meningitis....
    Medicine Products: